Posted by Michael Wonder on 03 Sep 2019
Price rises above inflation already standard for drugs
3 September 2019 - In the past three years, more than half of all sales growth for the top 45-selling drugs was due to price increases.
In your editorial “The Right’s Left Turn on Drug Prices”, you criticise a new U.S. Senate Finance Committee proposal to cap Medicare drug-price increases at the rate of inflation.
You predict that the measure will “cause companies to launch drugs at higher prices”—a claim that is plausible only if we assume that industry executives aren’t currently setting the profit-maximising price. That seems unlikely.
